Pitolisant hydrochloride is under clinical development by Harmony Biosciences and currently in Phase II for Prader-Willi Syndrome (PWS). According to GlobalData, Phase II drugs for Prader-Willi Syndrome (PWS) have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pitolisant hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pitolisant hydrochloride overview
Pitolisant hydrochloride (Wakix, Ozawade) is a central nervous system drug. It is formulated as film-coated tablets for oral route of administration. Wakix is indicated in adults for the treatment of narcolepsy with or without cataplexy. Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP).
It is under development for the treatment of obstructive sleep apnea, excessive diurnal sleepiness in patients with moderate to severe obstructive sleep apnoea (OSA) syndrome, obstructive sleep apnea and narcolepsy with or without cataplexy in adults and pediatrics and idiopathic hypersomnia. It is also under development for prader-willi syndrome (PWS), fatigue, cognitive impairment and myotonic dystrophy. It was also under development for the treatment of bipolar depression and cognitive-enhancing effects in schizophrenia or schizoaffective disorder and alcohol use disorder and Parkinson's disease.
Harmony Biosciences overview
Harmony Biosciences is a commercial-stage, pharmaceutical company that discovers, develops and commercializes therapies for neurological indications. The company’s product includes WAKIX, a first-in-class molecule specially design to increase histamine signaling in the brain by binding to H3 receptors. Harmony Biosciences is investigating Pitolisant, a histamine-3 receptor (H3R) antagonist-based program to treat idiopathic hypersomnia, Prader-Willi syndrome and myotonic dystrophy and HBS-102, a melanin-concentrating hormone receptor 1 (MCHR1) antagonist for Prader-Willi syndrome. Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania, the US.
For a complete picture of Pitolisant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.